The European Commission has unconditionally approved the proposed acquisition of Seagen (SGEN) by Pfizer (PFE), under the EU Merger Regulation. The Commission concluded that the transaction would not raise competition concerns in the European Economic Area. Moreover, the Commission found that the transaction was unlikely to have negative impact on prices, given that the parties’ offerings are differentiated and complementary and that the markets for the treatment of the various cancer types examined are sufficiently competitive. The Commission therefore concluded that the proposed merger would not raise competition concerns and cleared the transaction unconditionally.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- LLY vs. PFE: Which Pharma Stock is the Better Buy?
- Alphabet Stock (NASDAQ:GOOGL) Q3 Earnings Preview: Can Its Strength be Sustained?
- Pfizer (NYSE:PFE) Slides despite EU Nod to Seagen Acquisition
- Pfizer prices Paxlovid at $1,400 for five-day regimen, WSJ reports
- AN2 Therapeutics receives license from UGA for Chagas disease treatment